Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXT-ASSESS: Naoxintong for Coronary Plaque in AMI
NCT05278182Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Dec 2022
- Primary completion
- Jun 2025
- Modality
- Botanical Extract
- Countries
- 1
01
Overview
Randomised, double-blind trial in myocardial infarction (MI) and Coronary atherosclerosis (CAD) comparing Naoxintong with Placebo (2 arms). Primary endpoints: Plaque composition by VH-IVUS at 12 months and Plaque fibrous cap thickness at 12 months. Status: unknown.
02
Drugs
naoxintong
03
Conditions
myocardial infarction (MI)Coronary atherosclerosis (CAD)
Beyond the preview
Go deeper on NCT05278182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278182.